Epidemiology and Molecular Biology Unit and Irish Meningococcal and Meningitis Reference Laboratory, Children's University Hospital, Dublin, Ireland.
Epidemiol Infect. 2011 May;139(5):783-90. doi: 10.1017/S0950268810001743. Epub 2010 Jul 19.
The 7-valent pneumococcal conjugate vaccine (PCV7) was included in the routine infant immunization schedule in Ireland in September 2008. We determined the serotype of 977 S. pneumoniae isolates causing invasive disease between 2000-2002 and 2007-2008, assessed for the presence of the recently described serotype 6C and determined the susceptibility of isolates during 2007-2008 to penicillin and cefotaxime. Serotype 14 was the most common serotype during both periods and 7·7% of isolates previously typed as serotype 6A were serotype 6C. During 2000-2002 and 2007-2008, PCV7 could potentially have prevented 85% and 74% of invasive pneumococcal disease in the target population (i.e. children aged <2 years), respectively. The level of penicillin non-susceptibility was 17% in 2007-2008. Ongoing surveillance of serotypes is required to determine the impact of PCV7 in the Irish population and to assess the potential of new vaccines with expanded valency.
2008 年 9 月,七价肺炎球菌结合疫苗(PCV7)被纳入爱尔兰常规婴儿免疫计划。我们确定了 2000-2002 年和 2007-2008 年期间引起侵袭性疾病的 977 株肺炎链球菌分离株的血清型,评估了最近描述的血清型 6C 的存在情况,并确定了 2007-2008 年分离株对青霉素和头孢噻肟的敏感性。在两个时期,血清型 14 都是最常见的血清型,85%和 74%,之前被定型为血清型 6A 的分离株分别是血清型 6C。2000-2002 年和 2007-2008 年,PCV7 可能分别预防了目标人群(即<2 岁儿童)中 85%和 74%的侵袭性肺炎球菌病。2007-2008 年,青霉素不敏感率为 17%。需要进行血清型的持续监测,以确定 PCV7 在爱尔兰人群中的影响,并评估具有扩展价的新疫苗的潜力。